Prostatype Genomics AB

📍 Stockholm, Sweden🗓 Founded 2007👥 13 employees💰 Last funded Jan 2017
Medical Equipment Manufacturing🌐 prostatypegenomics.com
Website LinkedIn
Prostatype Genomics offers prostate cancer patients a decision support for the most optimal treatment option! We developed a test system called 'Prostatype® Test System'. The system is based on a gene expression test, which measures the expression of three carefully selected embryonic stem cell genes in prostate cancer core needle biopsies. In conjunction with currently used clinical parameters, the PrTS predicts overall survival in relation to treatment. The Prostatype® Test System helps to choose the optimal treatment strategy for each patient. This secures quality of life for patients with a low risk tumor without jeopardizing safety for patients with aggressive tumors.
3
Total investors
0
Early stage
0
Mid stage
1
Late stage
2007
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Sweden
2
Germany
1
Investor activity2013–2017 · investors recorded per year
2013120172
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Prostatype Genomics AB?
Prostatype Genomics AB has 3 investors on record on gritt.io and 1 late-stage investors.
When did Prostatype Genomics AB last raise funding?
The most recent investment in Prostatype Genomics AB recorded on gritt.io was in January 2017.
When was Prostatype Genomics AB founded?
Prostatype Genomics AB was founded in 2007.
What industry is Prostatype Genomics AB in?
Prostatype Genomics AB operates in Medical Equipment Manufacturing. Find similar Medical Equipment Manufacturing investors on gritt.io.
Where is Prostatype Genomics AB based?
Prostatype Genomics AB is headquartered in Stockholm, Sweden.